Trulicity (dulaglutide) is a prescription drug that can cause weight loss in some people but is not approved for this use.

RANI READ THE FULL RANI RESEARCH REPORT On February 5 th , Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shared its preclinical readout from the RT-116 study demonstrating successful oral delivery of ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that it costs $100 to $300 million to develop a biosimilar and that it takes ...

Microdosing GLP-1 has been touted for everything for weight management to perimenopause symptoms. But is it all it’s cracked ...

At the recent SEC meeting for Endocrinology and Metabolism held on 13th January 2025, the expert panel reviewed the ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Glucagon-like peptide-1 (GLP-1) is a well-known medication used by physicians to treat Type 2 diabetes. GLP-1 has also become ...

Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders ...